Table 2. Baseline characteristic of patients undergoing second-line treatment.
| Characteristic | Total (n=88) |
|---|---|
| Age (y) | |
| Mean±SD | 56.19±10.09 |
| Median(min–max) | 55.0 (36.0–83.0) |
| Sex | |
| Male | 66 (75.0) |
| Female | 22 (25.0) |
| Body mass index (missing=5) | |
| Mean±SD | 23.65±3.60 |
| Median (min–max) | 23.41 (16.83–37.79) |
| IT and TT | |
| IT | 16 (18.2) |
| TT | 72 (81.8) |
| Treatment-free interval | |
| ≥1 year | 20 (22.7) |
| <1 year | 68 (77.3) |
| Anemia | |
| No | 39 (44.3) |
| Yes | 49 (55.7) |
| Hypercalcemia | |
| No | 87 (98.9) |
| Yes | 1 (1.1) |
| Neutrophilia (≥6,000) | |
| No | 76 (86.4) |
| Yes | 12 (13.6) |
| ECOG PS (≥1) | |
| No | 84 (95.5) |
| Yes | 4 (4.5) |
| Platelet (≥450 K) | |
| No | 87 (98.9) |
| Yes | 1 (1.1) |
| Tumor stage | |
| T1–T2 | 33 (37.5) |
| T3–T4 | 39 (44.3) |
| Tx. | 7 (8.0) |
| Unknown | 9 (10.2) |
| Cytoreductive nephrectomy | |
| No | 61 (69.3) |
| Yes | 27 (30.7) |
| mRCC | |
| Synchronous | 70 (79.5) |
| Metachronous | 18 (20.5) |
| Fuhrman nuclear grade | |
| Low | 3 (3.4) |
| High | 39 (44.3) |
| Unknown | 46 (52.3) |
| Histology | |
| Clear cell | 54 (61.4) |
| Non-clear cell | 3 (3.4) |
| Unknown | 31 (35.2) |
| 2nd Treatment duration (mo) | |
| Median (min–max) | 3.68 (0.23–84.03) |
| Overall survival (mo) | |
| Median (95% CI) | 10.65 (8.52–14.33) |
| Progression-free survival (mo) | |
| Median (95% CI) | 4.50 (2.99–5.22) |
| Cancer-specific survival (mo) | |
| Median (95% CI) | 12.0 (9.63–18.97) |
Values are presented as number (%) unless otherwise indicated.
SD, standard deviation; IT, immunotherapy; TT, targeted therapy; ECOG PS, Eastern Cooperative Oncology Group Performance Status; mRCC, metastatic renal cell carcinoma; CI, confidence interval.